Abstract
Optimal treatment (tx) of patients (pts) with NSCLC and uncommon EGFR mutations (non Del19/L858R) remains unclear due to limited clinical data. We previously developed a database of 693 pts with NSCLC and uncommon EGFR mutations treated with afatinib (afa) in RCTs and real-world practice. Here, we provide an update of >1000 pts, with more data on specific mutations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
